News und Analysen
Antibe Therapeutics Engages Stern IR for Investor Relations Services
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announces that it has engaged Stern Investor Relations, Inc. (“Stern IR”) to expand the Company’s investor relations program and support
NanoString and Bio-Techne Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and Bio-Techne (NASDAQ:TECH), a global life sciences company
Vifor Pharma Group Reports Continued Growth in H1 2020
Regulatory News:
Vifor Pharma Group reported growth in H1 2020, despite challenges to patient access conditions caused by the COVID-19 pandemic. The financial guidance has been updated to reflect
Vifor Pharma Gruppe wächst auch im 1. Halbjahr 2020 weiter
Regulatory News:
Die Vifor Pharma Gruppe ist trotz der Herausforderungen, die Patienten auch während der COVID-19-Pandemie zu erreichen, im 1. Halbjahr 2020 weiter gewachsen. Die Finanzprognose
Simulations Plus Announces Pricing of $100 Million Underwritten Offering of Common Stock
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company
STAAR Surgical Reports Second Quarter 2020 Results
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the
Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported second quarter 2020 financial results and recent business highlights.
“We are very excited about our global
Hanger Reports Second Quarter 2020 Financial Results
Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced its financial results for the second quarter ended June 30, 2020
Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its
EnWave Signs Commercial License and Equipment Purchase Agreement with Orto Al Sole to use REV™ Technology in Italy
Vancouver, B.C., August 5, 2020 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) announced today
EnWave unterzeichnet kommerziellen Lizenz- und Gerätekaufvertrag mit Orto Al Sole für Nutzung der REV™ Technologie in Italien
Vancouver, B.C., 5. August 2020 - Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) gab
Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today treatment of the first patient in the Phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib, Clovis’ investigational
LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer
Pfizer Inc. (NYSE:PFE) today announced that the Phase 3 CROWN study of LORBRENA® (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell
Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the virtual Canaccord Genuity Global Growth
Charles River Laboratories Announces Second-Quarter 2020 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2020. For the quarter, revenue was $682.6 million, an increase of 3.8% from $657.6
IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that
True Leaf informiert über aktuellen Stand des Umstrukturierungsprozesses
Vernon (British Columbia), 5. August 2020. True Leaf Brands Inc. (CSE: MJ) (OTCQX: TRLFF) (FWB: TLA) („True Leaf“) gibt heute bekannt, dass True Leaf und seine Tochtergesellschaften am 31.
True Leaf Provides Update on Restructuring Process
Vernon, BC - August 5, 2020 - True Leaf Brands Inc. (CSE: MJ) (OTCQX: TRLFF) (FSE: TLA) (“True Leaf”) announced today that, on July 31, 2020, True Leaf and its subsidiaries obtained Orders
Novavax: Nachbörsliche Räuberpistole!
Gestern Abend kam es nachbörslich zu einer wilden Berg- und Talfahrt bei der Aktie des US-amerikanischen Biotechunternehmens Novavax (WKN: A2PKMZ). Der Grund hierfür wirkt kurios.
Zunächst einmal
Evotec: Vorstand streckt Fühler nach Antisense-Startup aus
Evotec (WKN: 566480) geht seine nächste strategische Partnerschaft ein. So wurde, wie heute vermeldet, mit dem Marburger Next-Generation-Wirkstoffforscher Secarna Pharmaceuticals eine Kooperation im
QIAGEN Reports Full Results for Second Quarter and First Half Of 2020
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced full results of operations for the second quarter and first half of 2020, with net sales and adjusted earnings per share (EPS) in
Xencor Reports Second Quarter 2020 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial
QIAGEN meldet vollständige Ergebnisse des zweiten Quartals und des ersten Halbjahrs 2020
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die vollständigen Ergebnisse der operativen Tätigkeit für das zweite Quartal und das erste Halbjahr 2020 bekannt, wobei der